Qu Biologics

July 30, 2018July 30, 2018

Qu Biologics Recruiting Crohn’s Patients in Canada for Phase 2 Trial, Hosting Webinar

News

Qu Biologics has started enrolling patients in the RESTORE Phase 2 trial to evaluate its lead investigative immunotherapy, QBECO SSI, in patients with moderate to severe Crohn’s disease. The study ... Read more

April 23, 2018April 23, 2018

Investigational QBECO SSI Therapy Enters Phase 2 Clinical Trial for Crohn’s

News

Qu Biologics soon will begin recruiting participants for a Phase 2 clinical trial to continue investigating the company’s special platform of immunotherapies, collectively called Site Specific Immunomodulators (SSIs), as a potential ... Read more

October 5, 2017October 5, 2017

Genetic, Immune Biomarkers Can Help Predict Response to QBECO SSI Treatment, UC Trial Suggests

News

Detection of specific genetic alterations and immunological biomarkers can help predict the response to QBECO SSI immunotherapy in patients with inflammatory bowel disease (IBD). This finding resulted from the analysis ... Read more

April 28, 2017

Immune Therapy Shows Response and Remission in Crohn’s Patients, Study Finds

News

Patients with Crohn’s disease benefit from treatment with a new platform of immunotherapies designed to restore the body’s innate immune system, a study has found. The announcement was made by ... Read more

December 29, 2015December 29, 2015

Clinical Trials Underway into Immunotherapies for Crohn’s Disease and Ulcerative Colitis

News

Qu Biologics Inc. recently provided an update for ongoing clinical trials assessing the company’s lead candidate for inflammatory bowel diseases (IBD), namely ulcerative colitis and Crohn’s disease. The company also announced it has ... Read more